I
IMMUNOVANT INC
NASDAQ: IMVT (Immunovant, Inc.)
Last update: 3 hours ago41.82
0.00 (0.00%)
| Previous Close | 41.82 |
| Open | 42.16 |
| Volume | 683,201 |
| Avg. Volume (3M) | 1,721,934 |
| Market Cap | 8,638,032,896 |
| Price / Book | 11.20 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Immunovant, Inc. | Mixed | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 30 Jun 2026 | 9,341,151 |
| Farallon Capital Management, L.L.C. | 30 Jun 2026 | 5,805,000 |
| Baker Bros. Advisors Lp | 30 Jun 2026 | 5,435,220 |
| Two Seas Capital Lp | 30 Jun 2026 | 3,148,505 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |